Abstract
Abnormal are the malignant cells. The genome is abnormal including chromosomal translocations, gene deletions or mutations. Malignant cell seems to be in an irreversible state. Therefore the only way to treat a patient with cancer is to eliminate the tumor by surgery, radiotherapy, chemotherapy and more recently immunotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Borrow J., Goddard A.D., Sheer D. and Solomon E. (1990) Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science, 249: 1577–1580.
Castaigne S., Chomienne C., Daniel MT, Ballerini P., Berger R., Fenaux P., Degos L. (1990) All trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 76: 1704–1709.
Castaigne S., Lefebvre P., Chomienne C., Sue E., Rigal-Huguet F., Gardin C., Delmer A., Archimbaud E., Tilly H., Janvier M., Isnard F., Travade P., Montfort L., Delannoy A., Rapp MH., Christian G., Montastruc M., Weh H., Fenaux P., Dombret H., Gourmel B. and Degos L. (1993) Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute preomyelocytic leukemia. Blood, 82: 3560–3563.
Castaigne S., Balitrand N., de The H., Dejean A., Degos L. and Chomienne C. (1992) A PML/RAR alpha fusion transcript is constantly detected by RNA based polymerase chain reaction in acute promyelocytic leukemia. Blood, 79: 3110–3115.
Chomienne C., Ballerini P., Balitrand N., Daniel MT., Fenaux P., Castaigne S., Degos L. (1990) All trans retinoic acid in acute promyelocytic leukemia. II. In vitro studies: structure function relationship. Blood, 76: 1710–1717.
Chomienne C., Ballerini P., Balitrand N., Huang ME., Krawice I., Castaigne S., Fenaux P., Tiollais P., Dejean A., Degos L., de The H. (1990) The retinoic acid receptor alpha gene is rearranged in retinoic acid sensitive promyelocytic leukemia. Leukemia, 4: 802–807.
Chomienne C., Balitrand N., Ballerini P., Castaigne S., de The H., Degos L. (1991) All trans retinoic acid modulates the retinoic receptor alpha in promyelocytic cells. J. Clin. Invest., 88: 2150–2154.
Cornic M., Delva L., Guidez F., Balitrand N., Degos L., Chomienne C. (1992) Induction of retinoic acid binding protein in normal and malignant human myeloid cells by retinoic acid in AML3 patients. Cancer Res., 52: 3329–3334.
Daniel MT., Kiken M., Romagne O., Barbey S., Bazarbachi A., Stadler M., Guillemin M.C., Degos L., Chomienne C., de The H. (1993) PML protein expression in haematopoietic and APL cells. Blood, 82: 1858–1867.
Degos L., Chomienne C., Daniel MT., Berger R., Dombret H., Fenaux P., Castaigne S. (1990) Treatment of frist relapse in acute promyelocytic leukemia with all trans retinoic acid. Lancet, 2: 1440.
de The H., Chomienne C., Lanotte M., Degos L., Dejean A. (1990) The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature, 347: 558–561.
de The H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. (1991) The PML-RAR fusion mRNA generated by the t(15;17) trans location in acute promyelocytic leukemia encodes a functionnally altered RAR. Cell, 66: 675–684.
Dombret H., Sutton L., Duarte M., Daniel MT., Leblond V., Castaigne S., Degos L. (1992) Combinet therapy with all-trans retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. Leukemia, 6: 1237–1242.
Fenaux P., Castaigne S., Dombret H., Chomienne C., Duarte M., Archimbaud E., Lamy T., Tibeghien P., Tilly H., Dufour P., Cransac M., Guerci A., Sadoun A. and Degos L. (1991) All-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: a pilot study. Blood (ASH Abstract n° 305 — plenary session) p 79a.
Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P., Lamy T., Tilly H., Guerci A., Maloisel F., Bordessoule D., Sadoun A., Tiberghien P., Fegueux N., Daniel MT., Chomienne C., Degos L. (1992) All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood, 80: 2176–2181.
Fenaux P., Le Deley MC., Castaigne S. et al (1993) Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood, 82: 3241–3249.
Frankel SR., Eardley A., Lauwers G., Weiss M. and Warrel RP (1992) The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann. Intern. Med, 117: 292–296.
Housset M., Daniel MT, Degos L. (1982) Small doses of ARA-C in the treatment of acute myeloid leukemia: differentiation of myeloid leukemia cells ? Brit. J. Haematol. 51: 125–129.
Huang M., Yu-Chen Y., Shu-Rong C., Lu MX., Zhoa L., Gu LJ., Wang ZY (1988) Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 73: 567.
Kakizuka A., Miller WH., Umesono K. et al (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 66: 663–674.
Muindi JF., Young CW (1993) Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome p-450 isoforms. Cancer Res, 53: 1226–1229.
Pandolfi PP, Grignani F., Alcalay M. et al (1991) Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene, 6: 1285–1292.
Rousselot P., Hardas B., Patel A., Guidez F., Gaken J., Castaigne S., Dejean A., de The H., Degos L., Farzaneh F., Chomienne C. (1994) The PML/RAR alpha gene product of the t(15; 17) translocation inhibits retinoic acid induced differentiation and mediated transactivation in human myeloid cells. Oncogene, 9: 545–551.
Rowley JD., Golomb HM., Gougherty C., (1977) 15/17 translocation: a consistent chromosomal change in acute promyelocytic leukaemia. Lancet, 1: 549–550.
Sachs L. (1978) Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells. Nature, 274: 535.
Tilly H., Castaigne S., Bordessoule D., Casassus P., Le Prise P., Tertian G., Desablens B., Henry-Amar M., Degos L. (1990) Low dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J. Clin. Oncol., 8: 272–279.
Wang ZY, Degos L. (1993) Retinoic acid in hematological malignancies. International Symposium, Shanghai, Chine 19–21 octobre 1993.
Warrell RP., Muindi J., Frankel SR., Jakubowski A., Dmitrovsky E., Miller WH. (1991) Continuous treatment with all trans retinoic acid progressively decreases plasma drug concentrations: implications for relapse and resistance in acute promyelocytic leukemia. Blood (ASH abstract n° 1063, p. 268a.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Degos, L. (1996). Differentiation Therapy of Acute Promyelocytic Leukemia. In: Tsiftsoglou, A.S., Sartorelli, A.C., Housman, D.E., Dexter, T.M. (eds) Tumor Biology. NATO ASI Series, vol 99. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61180-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-61180-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64735-2
Online ISBN: 978-3-642-61180-3
eBook Packages: Springer Book Archive